A new analysis of genetic data from over 13,500 participants in the ASPREE clinical trial suggests that low-dose aspirin may be associated with a significantly lower risk of dementia in older adults with a specific genetic profile. The study found that individuals with a genetic profile linked to platelet count had a 70% lower relative risk of developing dementia when taking aspirin, compared to those who received a placebo.
However, the potential benefits of aspirin were accompanied by a higher risk of major bleeding, particularly in the group with the highest genetic scores. In this group, 4.4% of aspirin users experienced major bleeding, compared to 2.1% of those who received a placebo.
Platelet Biology as a Key to Dementia Prevention
Researchers from Monash University emphasized the importance of further studying platelet biology in relation to dementia. They noted that the identified genetic association was not linked to established genetic risk factors for Alzheimer’s disease and other forms of dementia, but rather pointed to the need for further investigation into the role of platelets in dementia prevention.
The study’s lead author, Peter Fransquet, stated that the findings raise the possibility of personalized dementia prevention strategies, where individuals with specific genetic profiles are identified as potential candidates for preventive treatments.
International Implications and the Need for Further Research
The study’s findings have significant implications for international audiences, particularly in countries with aging populations. Dementia is a major public health concern worldwide, and the potential for aspirin to reduce the risk of dementia in specific genetic groups could have far-reaching consequences for healthcare policies and resource allocation.
The researchers emphasize that the results must be confirmed in other studies and populations before they can guide medical recommendations. A clinical trial specifically designed for individuals with the identified genetic profile is necessary to further investigate the relationship between aspirin and dementia risk.
Image: Ilustracion generada con IA
Sources consulted
- Science Daily: Low-dose aspirin linked to 70% lower dementia risk, but there’s a catch
- UA.NEWS: Aspirin linked to a 70% reduction in relative dementia risk in genetic group — ScienceDaily
- LBC: Aspirin shortages expose the NHS’s dangerous lack of planning
Adrian Velk is a global affairs journalist focused on breaking news, geopolitics, and societal trends. With a sharp eye for detail and a commitment to accuracy, he delivers timely reporting that helps readers understand the fast-moving world around them. His work blends factual depth with clear storytelling, making complex events accessible to a broad audience.
